Professional Documents
Culture Documents
Professor
Department of Biology
Boise State University
Neurodegenerative disease
characterized by abnormalities
in the brain affecting neurons
Currently, AD is the 8th leading cause of death
in the USA
y neuron AD ne
AD is characterized by several structural
abnormalities in the brain
Neurofibrillary
Tangles
What is beta-amyloid?
Presently in clinical
trials and is not yet FDA
approved
urrently FDA-approved Treatments
These class of
drugs include
Exelon® and
Aricept®
Benefits are minimal: Can we do better?
Namenda (Memantine): Glutamate-receptor
antagonist
Drug was
approved in
the USA in
October, 2003
May achieve
additive
benefits when
taken
together with
Aricept
Drugs in development that will attack
Beta-Amyloid
By injecting
beta-amyloid,
antibodies will be
made against it
which then will
bind to beta-
amyloid on plaques.
Unimmunized patient
Secretase inhibitors: Block
the Molecular Scissors that
Produce to Beta-Amyloid
Turning off the faucet: removing
beta-amyloid once it is produced
This strategy is still in the early
stages of testing
Eli Lilly reported on a Phase I study
in volunteer subjects without AD using
a compound, LY450139, which interferes
with one set of the “scissors”
responsible for producing beta-amyloid;
Gamma secretase.
Phase III
Phase III
The APP gene is on Chromosome 21,
and individuals with DS have an extra
copy (3 instead of 2). This is why they
eventually exhibit symptoms of AD
All individuals with DS over the age of
40 years have neuropathology consistent
with a diagnosis of Alzheimer’s disease